CHICAGO—David Daikh, MD, PhD, professor of medicine at the University of California San Francisco and chief of the Rheumatology Division at the San Francisco VA Medical Center, said the overlap between malignant disease and rheumatic disease means rheumatologists should stay aware that more may be going on than just a rheumatic disorder. He made his…
The ACR’s State-of-the-Art Clinical Symposium: Rheumatologists Weigh in on Tough-to-Treat Cases, Paget’s Disease, Imaging
CHICAGO—A 49-year-old woman has had RA for eight years. She has a rheumatoid factor reading of 35, an aCCP reading of 160, erythrocyte sedimentation rate of 42, plus erosions. She has been on methotrexate. She tried etanercept for six months, but then it stopped working. She was on 40 mg of adalimumab weekly, but it…
The ACR Partners with Coalition, Patient Advocacy Groups to Advocate for Rheumatology
In terms of getting our message heard in Washington, D.C., rheumatology faces a David vs. Goliath battle on several levels. Many industries have far greater resources, use multiple lobbying firms, and have advertising and lobbying budgets that eclipse ours by several hundred-fold. Rheumatology is far smaller than most other medical specialties; our membership is a…
Rheumatology Research Foundation Announces Award Recipients
On July 1, 2015, the Rheumatology Research Foundation awarded more than 80 grants to a wide range of rheumatology trainees and professionals. The recipients, who submitted applications in 2014, will receive funding for essential education and training, as well as innovative research projects. Their applications were closely examined by experts in different areas of the…
White House Is Open to Working with Congress on Disease Research Bill
WASHINGTON (Reuters)—The White House said on Wednesday it was open to working with Congress on a bill that would invest in disease research and would be paid for with sales of oil from U.S. emergency reserves. The House of Representatives is considering a bipartisan bill that would increase funding for the U.S. National Institutes of…
Biosimilar Drug Updates Reported from EULAR
At the 2015 meeting of the European League Against Rheumatism in June, multiple studies were presented comparing the use of different biosimilar and biologic drugs in treating rheumatoid arthritis…
Rheumatology Community Applauds CMS Guidance Providing ICD-10 “Safe Harbor” Period, Encourages Further Action to Ensure Responsible Transition
ATLANTA, Ga.—The American College of Rheumatology (ACR) today praised the Centers for Medicare and Medicaid Services (CMS) for issuing new guidance to provide a 12-month “safe harbor” period for physicians following the Oct. 1 implementation of the ICD-10 code set. The ACR has led legislative and grassroots efforts to responsibly address the transition to the…
E-Learning in Physiotherapy
A physiotherapy-specific, Web-based e-learning platform, “RAP-el,” was studied to determine its effectiveness in assisting physiotherapists with the best-practice management of rheumatoid arthritis (RA). It was shown to improve self-reported confidence, likely practice behaviors and satisfaction in physiotherapists’ ability to manage people with RA, and improve their clinical knowledge in several areas…
Nurses May Be Key to Long-Term Clinical Trial Success
After completing a 10-year clinical trial examining treatment strategies for rheumatoid arthritis, Dutch researchers used a questionnaire to determine the study conditions and individual motivators that kept 60% of patients participating long term…
EULAR 2015: What’s New in RA Research
ROME, Italy—Even with classification criteria that have been updated and refined over time, rheumatoid arthritis (RA) is still a diagnosis that ultimately has to be made with clinical judgment, said Ronald van Vollenhoven, MD, PhD, professor of medicine and chief of clinical therapy research in inflammatory diseases at the Karolinska University in Sweden. His remarks…
- « Previous Page
- 1
- …
- 198
- 199
- 200
- 201
- 202
- …
- 301
- Next Page »